Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Will The Cell Free DNA (cfDNA) Testing Market Valuation Change Between Now And 2029?

The market for cell free dna (cfDNA) testing has seen significant growth in recent times. This market is projected to increase from a value of $8.74 billion in 2024 to about $10.84 billion in 2025, representing a compound annual growth rate (CAGR) of 24.0%. The expansion during this historical period is due in part to a surge in the usage of cfDNA testing within prenatal care, as well as an escalation of cfDNA analysis implementation, heightened interest in cfDNA research in diverse medical disciplines, and an increase in acquiring regulatory body approvals.

In the coming years, the market for cell-free DNA (cfDNA) testing is projected to undergo significant expansion, expected to rise to a value of $24.34 billion in 2029, reflecting a compound annual growth rate (CAGR) of 22.4%. This growth, expected throughout the forecast period, can be linked to various factors, including the shift towards bespoke healthcare, improvements in medical facilities, an aging population and heightened frequency of cancer. There’s also an increased usage of precision medicine, heightened awareness and acceptance of liquid biopsy methods, and an upswing in investment in cfDNA research. Key trends over the forecast period comprise the adoption of liquid biopsy technologies, progress in Next-Generation Sequencing (NGS) technology, the incorporation of AI and machine learning into cfDNA testing procedures, the creation of point-of-care cfDNA tests, and the application of cloud-based platforms for data storage and examination.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15757&type=smp

What Underlying Factors Are Supporting The Cell Free DNA (cfDNA) Testing Market Growth?

The increase in cancer cases is predicted to be a major driver of growth for the cell-free DNA (cfDNA) testing market. Cancer, a set of diseases defined by abnormal cells growing uncontrollably and spreading throughout the body, can cause severe damage if unchecked. The prevalence of this illness can be attributed to aging populations, lifestyle changes, environmental factors, and enhanced detection and diagnostic methods. cfDNA testing serves as a tool to identify cancer-related genetic mutations at an early stage, often before any symptoms manifest. Early detection permits timely treatment, thereby improving patient prognosis and chances of survival by catching the disease in its earliest stages. As per the World Health Organization (WHO), a Switzerland-based intergovernmental organization, a projection for February 2024 indicates over 35 million new cancer cases in 2050, marking a 77% rise from the estimated 20 million cases in 2022. As such, the escalating incidence of cancer is fuelling the expansion of the cell-free DNA (cfDNA) testing market.

Which Sub-Segments Are Driving Growth Within The Cell Free DNA (cfDNA) Testing Market?

The cell free dna (cfdna) testingmarket covered in this report is segmented –

1) By Product: Donor-Derived Cell-Free DNA; Circulating Cell-Free Tumor DNA; Cell-Free Fetal DNA

2) By Platforms: Next Generation Sequencing (NGS); rPCR And Multiplexed PCR; qPCR And dPCR; Other platforms

3) By Application: Oncology; Non-Invasive Prenatal Test (NIPT); Gynecology; Transplantation; Other Applications

Subsegments:

1) By Donor-Derived Cell-Free DNA: Organ Transplant Monitoring; Graft Rejection Detection

2) By Circulating Cell-Free Tumor DNA: Cancer Detection; Minimal Residual Disease Monitoring; Liquid Biopsy

3) By Cell-Free Fetal DNA: Non-Invasive Prenatal Testing (NIPT); Fetal Genetic Disorder Screening

What Key Trends Are Driving Growth In The Cell Free DNA (cfDNA) Testing Market?

Leading businesses in the cell-free DNA (cfDNA) testing market are introducing novel technologies such as the liquid biopsy tests, which provide superior sensitivity, specific accuracy, and efficiency in identifying cancer-driven mutations and genetic changes. Liquid biopsy tests are diagnostic techniques that enable oncologists to study the circulating cell-free DNA that tumor cells release, aiding in the formulation of customized, targeted treatment approaches. For example, in May 2023, the United States headquartered life sciences company Laboratory Corporation of America Holdings (Labcorp) unveiled Labcorp Plasma Focus. This newly created liquid biopsy test is intended for patients suffering from advanced or metastatic solid tumors. The test involves the analysis of circulating cell-free DNA (cfDNA) that tumor cells release from a routine blood sample, which keeps it minimally intrusive and delivers prompt results. It bolsters precision oncology access by detecting clinically significant biomarkers in several prevalent cancers such as non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, gastric cancers, and melanoma.

Which Companies Hold A Competitive Edge In The 871 Market?

Major companies operating in the cell free DNA (cfDNA) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Bio-Techne Corporation, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Invitae Corporation, Foundation Medicine Inc., Guardant Health Inc., Integrated DNA Technologies Inc., Caris Life Sciences Inc., Twist Bioscience Corporation, Adaptive Biotechnologies Corporation, Biodesix Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems Inc., Circulogene Theranostics LLC

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/cell-free-dna-cfdna-testing-global-market-report

Which Region Dominates The Cell Free DNA (cfDNA) Testing Market Today?

North America was the largest region in the cell-free DNA (cfDNA) testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell free DNA (cfDNA) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15757&type=smp

Browse Through More Reports Similar to the Global Cell Free DNA (cfDNA) Testing Market 2025, By The Business Research Company

Cellular Health Screening Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cellular-health-screening-global-market-report

Carboxymethylcellulose Cmc Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/carboxymethylcellulose-cmc-global-market-report

Autologous Cell Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autologous-cell-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model